Fenwick Represents Day One Biopharmaceuticals in $150 Million Public Offering

Fenwick represented Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company focused on the development of therapies for life-threatening diseases, in its underwritten public offering of 11,538,462 shares of its common stock at an offering price of $13.00 per share. Day One has also granted a 30-day option to the underwriters to purchase an additional 1,730,769 shareholders at the public offering price, minus underwriting discounts and commissions. Day One is expected to receive gross proceeds of $150 million, before deducting underwriting discounts and commission and other offering expenses.

J.P. Morgan, TD Cowen and Piper Sandler acted as joint book-runners for the offering. More information can be obtained on Day One’s website.

The Fenwick transaction team included corporate partners Robert Freedman and Julia Forbess and associates Arielle Trapp, Meg Moloney and Ankeet Ball.